Skip to content

News

Scailyte closes Series A funding with a CHF 6 million investment

Scailyte closes Series A funding with a CHF 6 million investment

Scailyte has successfully finished the Series A funding raising CHF 6 million from a Swiss family office, Mirabaud bank and previous investors. Peter Ibbotson, who has recently been promoted to the position of a Partner at Swisscom Ventures will replace Dominique Mégret on the Board of Directors of Scailyte.
Read More
Internship Women’s Health R&D

VACANCY: Internship in Women’s Health R&D

The internship in Women’s Health R&D will focus on our in vitro diagnostics development work in endometriosis.
Read More
nilogen and scailyte joining forces

Nilogen and Scailyte Are Joining Forces to Find the “Right” Treatment for Every Patient

Nilogen and Scailyte are joining forces to increase the success of cancer therapies in clinics and to advance personalized cancer treatment.
Read More
machine learning precision medicine

Machine learning meets multi-omics for precision medicine

Bringing industry and academia together to discuss the potential impact of single-cell analytics powered by machine learning for precision medicine.
Read More
Understanding Resistant to CAR-T Immunotherapy to Develop Better Next-generation Therapies

Understanding Resistant to CAR-T Immunotherapy to Develop Better Next-generation Therapies

Register for Scailyte's webinar on "Understanding Resistant to CAR-T Immunotherapy to Develop Better Next-generation Therapies".webinar single-cell endometriosis research
Read More
Making groundbreaking discoveries requires collaborations and joint-ventures.